Pulmatrix Merges with Cullgen in Strategic Biopharma Move
Deal News | Nov 13, 2024 | EIN
Biopharmaceutical company Pulmatrix, based in Framingham and listed on the Nasdaq, has announced its intention to merge with Cullgen, a privately-held drug developer headquartered in San Diego. Post-merger, the newly formed entity will operate under the Cullgen name and continue to trade on Nasdaq. The merger will result in Cullgen stakeholders controlling 96.4% of the company, with Pulmatrix shareholders possessing the remaining 3.6%. The newly combined entity will be led by Cullgen’s CEO, Dr. Ying Luo, with representation on the board from Pulmatrix. The merger signifies strategic growth, with an emphasis on progressing Cullgen's targeted protein degrader developments for clinical applications in cancer and other diseases. Pulmatrix, with its expertise in inhaled therapeutic products, will complement Cullgen's extensive research pipeline. The merger also comes in the backdrop of Pulmatrix's recent relocation of its headquarters from Bedford to Framingham upon offloading its lease to MannKind Corp.
Sectors
- Biopharmaceuticals
- Financial Markets
Geography
- United States – The companies involved are located and operating within the United States, with Pulmatrix based in Framingham, Massachusetts, and Cullgen in San Diego, California.
Industry
- Biopharmaceuticals – The article pertains to companies involved in the development and commercialization of drugs, particularly focusing on targeted protein degraders and inhaled therapeutics.
- Financial Markets – The merger involves companies trading on the Nasdaq exchange, indicating its relevance to stakeholders and investors in the financial markets.
Financials
- 3.6% – Percentage of the combined company that Pulmatrix stockholders will own after the merger.
- 96.4% – Percentage of the combined company that Cullgen owners will own after the merger.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Pulmatrix | Target company | Company | A Framingham-based biopharmaceutical company specializing in inhaled therapeutic products, listed on the Nasdaq. |
| Cullgen | Bidding Company | Company | A San Diego-based, privately-held drug developer focusing on targeted protein degrader technology. |
| Dr. Ying Luo | CEO of Cullgen | Person | Chief Executive Officer who will lead the merged entity. |
| Eric Casey | Source | Person | Staff writer at Worcester Business Journal, covering manufacturing and real estate. |